BUSINESS OVERVIEW
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange.
We unite AI with cutting-edge science to discover life-changing medicines.
Through the combined capabilities of its AI platform, its scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods.
The Benevolent Platform™ powers BenevolentAI’s in-house drug pipeline and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
A note from our CFO
"BenevolentAI’s aim is to create technology to drive a revolution in drug discovery and develop new medicines for patients with a higher probability of clinical success. We are on a firm financial footing and well-positioned to deliver on key value inflection points, drive value for all of our shareholders and cement our position as a global leader in AI-enabled drug discovery."
Nicholas Keher
Chief Financial Officer
Financial calendar
|
Date to be announced
2023 AGM
|
|
Date to be announced
Interim results for the six months ended 30 June 2023
|
EMAIL ALERTS
Get alerts for our announcements
Investor events, conference attendance and annual reporting.